PDCD1 and cancer: For the first time pembrolizumab, an anti-PD-1 monoclonal antibody, has been approved in cancer treatments that are based on the tumor biomarkers of high microsatellite instability or mismatch repair deficiency, regardless of the tumor’s original location (42).